

10/531,587

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:41:55 ON 23 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Mar 2006 VOL 144 ISS 13

FILE LAST UPDATED: 22 Mar 2006 (20060322/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>



=> d que

L1 STR



schizophrenia
 INVENTOR(S): Vacher, Bernard; Cuisiat, Stephane; Koek, Wouter;
 Colpaert, Francis
 PATENT ASSIGNEE(S): Pierre Fabre Medicament, Fr.
 SOURCE: Fr. Demande, 36 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845992	A1	20040423	FR 2002-12854	20021016
FR 2845992	B1	20050204		
CA 2502528	AA	20040429	CA 2003-2502528	20031016
WO 2004035561	A1	20040429	WO 2003-FR3053	20031016
W: AU, BR, CA, CN, JP, MX, US, ZA				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003301277	A1	20040504	AU 2003-301277	20031016
EP 1551821	A1	20050713	EP 2003-808761	20031016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
BR 2003015365	A	20050823	BR 2003-15365	20031016
JP 2006508080	T2	20060309	JP 2004-544396	20031016
US 2006014827	A1	20060119	US 2005-531587	20050418
PRIORITY APPLN. INFO.:			FR 2002-12854	A 20021016
			WO 2003-FR3053	W 20031016
OTHER SOURCE(S):		MARPAT 140:339186		
GI				



AB Title compds. I [W = CH, CH₂, CHCH₃, CCH₃, C(CH₃)₂, a group C(CH₂)₂ (i.e., a carbon atom carrying two methylene groups so as to form a spirocyclopropane ring) or C(CH₂)₃ (i.e., a carbon atom carrying two methylene groups so as to form a spirocyclobutane ring) with provisos; X =

CH, N; Y = H, F; their salts and hydrates of the salts of addition with mineral acids or the pharmaceutically acceptable organic acids, their tautomers, pure enantiomers and the racemic mixts. of enantiomers] were prepared as dopaminergic D2 antagonists drugs for treating of schizophrenia. For example, II was prepared by reductive alkylation of 3-(Cyclopenten-1-yl)benzaldehyde (preparation given) with 2-(2,2-Dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethylamine (preparation given) in CH₂Cl₂ in the presence of MgSO₄ at 60°. Selected I displayed affinity for D2 and 5HT_{1A} receptors, with pK_i ratios comparable to Nemonapride [pK_i(D2)/pK_i(5HT_{1A}) = 1.3]. I are potent and efficient dopaminergic antagonists without secondary effects such as catalepsy in animals. I are useful for treating schizophrenic psychoses.


IT 680203-70-7P, [2-(2,2-Dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl] [3-(cyclopenten-1-yl)benzyl]amine 680203-72-9P 680203-73-0P, [2-(Benzofuran-7-yloxy)ethyl] [3-(cyclopenten-1-yl)benzyl]amine 680203-75-2P 680203-77-4P, [2-(2-Methylbenzofuran-7-yloxy)ethyl] [3-(cyclopenten-1-yl)benzyl]amine 680203-81-0P 680203-84-3P, [2-(2,3-Dihydrobenzofuran-7-yloxy)ethyl] [3-(cyclopenten-1-yl)benzyl]amine 680203-89-8P 680203-90-1P 680203-92-3P 680203-93-4P 680203-94-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(dopamine D2 antagonist; preparation of 3-(cyclopenten-1-yl)benzyl- or 3-(cyclopenten-1-yl)heteroarylmethylamines as dopaminergic D2 antagonists for treating schizophrenia)

RN 680203-70-7 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 680203-72-9 CAPLUS


CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)oxy]ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 680203-70-7

CMF C24 H29 N O2

10/531,587




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 680203-73-0 CAPLUS

CN Benzenemethanamine, N-[2-(7-benzofuranyloxy)ethyl]-3-(1-cyclopenten-1-yl)-
(9CI) (CA INDEX NAME)



RN 680203-75-2 CAPLUS


CN Benzenemethanamine, N-[2-(7-benzofuranyloxy)ethyl]-3-(1-cyclopenten-1-yl)-
, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

10/531,587

CM 1

CRN 680203-73-0

CMF C22 H23 N O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 680203-77-4 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2-methyl-7-benzofuranyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



10/531,587


RN 680203-81-0 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2-methyl-7-benzofuranyl)oxy]ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 680203-77-4

CMF C23 H25 N O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 680203-84-3 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2,3-dihydro-7-benzofuranyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 680203-89-8 CAPLUS

Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-[(2,3-dihydro-7-benzofuranyl)oxy]ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 680203-84-3

CMF C22 H25 N O2




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



10/531,587

RN 680203-90-1 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-(spiro[benzofuran-2(3H),1'-cyclopropan]-7-yloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 680203-92-3 CAPLUS

CN Benzenemethanamine, 3-(1-cyclopenten-1-yl)-N-[2-(spiro[benzofuran-2(3H),1'-cyclopropan]-7-yloxy)ethyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 680203-90-1

CMF C24 H27 N O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


10/531,587

Double bond geometry as shown.



RN 680203-93-4 CAPLUS

CN Benzenemethanamine, N-[2-[(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)oxy]ethyl]-3-(2-fluoro-1-cyclopenten-1-yl)- (9CI) (CA INDEX NAME)



RN 680203-94-5 CAPLUS


CN Benzenemethanamine, N-[2-[(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)oxy]ethyl]-3-(2-fluoro-1-cyclopenten-1-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 680203-93-4

CMF C24 H28 F N O2

10/531,587




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>